A Randomized Controlled Trail of Uterosacral Ligament Suspension in the Treatment of Pelvic Organ Prolapse
Launched by LAN ZHU · May 13, 2024
Trial Information
Current as of February 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years with symptomatic stage II or higher uterine prolapse (C ≥ +1cm) and gynecological ultrasonography confirming cervical length ≥ 4cm. Concurrent anterior and/or posterior vaginal wall prolapse may be present.
- • Preoperative pelvic ultrasound and cervical screening show no abnormalities.
- • The patient does not have a desire for future fertility.
- • Willingness and ability to adhere to the follow-up treatment plan.
- • Competence to provide informed consent.
- Exclusion Criteria:
- • Suspected untreated lower genital tract tumor, accompanied by other uterine, ovarian, and cervical lesions requiring surgical intervention, indicating contraindication for uterine preservation.
- • Patients with a history of total hysterectomy/subtotal hysterectomy.
- • Patients who have previously undergone pelvic organ prolapse surgery or other pelvic floor surgeries.
- • Patients with contraindications for laparoscopic surgery, such as intestinal obstruction.
- • Patients with intestinal hernia.
- • Patients with gynecological and urinary tract infections, anticoagulant therapy, coagulation disorders, previous pelvic radiotherapy, as well as neurological or medical conditions affecting bladder and bowel function (such as multiple sclerosis, spinal cord injury, or residual neurological dysfunction caused by stroke), and patients with underlying conditions such as chronic pelvic pain, who are at higher risk for surgery.
- • Simultaneous anti-urinary incontinence surgery is required for this procedure.
Trial Officials
Lan Zhu, MD
Principal Investigator
Peking Union Medical College Hospital
About Lan Zhu
Lan Zhu is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on integrity and scientific rigor, Lan Zhu collaborates with leading healthcare professionals and institutions to design and execute clinical trials that address unmet medical needs. The organization prioritizes patient safety and ethical standards, ensuring that all trials adhere to regulatory guidelines while fostering a culture of transparency and collaboration. By leveraging cutting-edge methodologies and data-driven insights, Lan Zhu aims to contribute to the development of effective therapies that enhance patient outcomes and improve public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0